Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 16/20 | 0.82 |
| ▸ | TBXA2R | P21731 | 8/20 | 0.82 |
| ▸ | PTGDR | Q13258 | 5/20 | 0.82 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | DRD1 | P21728 | 1/20 | 0.68 |
| ▸ | CCKAR | P32238 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9879982 | 0.92 | PTGDR2 (0.85) | PTGDR2TBXA2RPTGDRABCB11CYP2C9 | |
| SCHEMBL8980256 | 0.91 | PTGDR2 (0.83) | PTGDR2TBXA2RPTGDRABCB11CYP2C9 | |
| SCHEMBL19799335 | 0.90 | PTGDR2 (0.82) | PTGDR2TBXA2RPTGDRABCB11CYP2C9 | |
| SCHEMBL18456875 | 0.90 | PTGDR2 (1.00) | PTGDR2TBXA2RPTGDRABCB11CYP2C9 | |
| SCHEMBL16558830 | 0.90 | PTGDR2 (1.00) | PTGDR2TBXA2RPTGDRABCB11CYP2C9 | |
| SCHEMBL3021349 | 0.88 | PTGDR2 (0.78) | PTGDR2TBXA2RPTGDRABCB11CYP2C9 | |
| SCHEMBL9431000 | 0.87 | TBXA2R (0.64) | PTGDR2TBXA2RPTGDRABCB11CYP2C9 | |
| SCHEMBL9833660 | 0.83 | PTGDR2 (0.87) | PTGDR2TBXA2RPTGDRABCB11CYP2C9 | |
| SCHEMBL833260 | 0.82 | PTGDR2 (0.70) | PTGDR2TBXA2RPTGDRABCB11CYP2C9 | |
| SCHEMBL833259 | 0.82 | PTGDR2 (0.70) | PTGDR2TBXA2RPTGDRABCB11CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2423190-A1 | Compounds Exhibiting PGD 2 Receptor Antagonism | Shionogi&Co., Ltd. (JP) | 2012-02-29 | — | — | EP | claimed |
| US-20090258922-A1 | COMPOUND EXHIBITING PGD2 RECEPTOR ANTAGONIST | SHIONOGI & CO., LTD. | 2009-10-15 | — | — | US | claimed |
| US-20050171143-A1 | Compound exhibiting pgd 2 receptor antagonism | SHIONOGI & CO., LTD. (JP) | 2005-08-04 | — | — | US | claimed |
| EP-1505061-A1 | COMPOUND EXHIBITING PGD 2 RECEPTOR ANTAGONISM | SHIONOGI & CO., LTD. (JP) | 2005-02-09 | — | — | EP | claimed |
| WO-2021066136-A1 | THERAPEUTIC AGENT FOR MUSCULAR DYSTROPHY | 国立大学法人東京大学 | 2021-04-08 | — | — | WO | disclosed |
| EP-2423190-A1 | Compounds Exhibiting PGD 2 Receptor Antagonism | Shionogi&Co., Ltd. (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-20090258922-A1 | COMPOUND EXHIBITING PGD2 RECEPTOR ANTAGONIST | SHIONOGI & CO., LTD. | 2009-10-15 | — | — | US | disclosed |
| US-7534897-B2 | Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism | SHIONOGI & CO., LTD. (JP) | 2009-05-19 | — | — | US | disclosed |
| US-20050171143-A1 | Compound exhibiting pgd 2 receptor antagonism | SHIONOGI & CO., LTD. (JP) | 2005-08-04 | — | — | US | disclosed |
| EP-1505061-A1 | COMPOUND EXHIBITING PGD 2 RECEPTOR ANTAGONISM | SHIONOGI & CO., LTD. (JP) | 2005-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258922-A1 | COMPOUND EXHIBITING PGD2 RECEPTOR ANTAGONIST | CYSLTR2, CYSLTR1, HRH2 | PTGDR2 7/4885TBXA2R 18/4885PTGDR 8/4885 |
| US-20050171143-A1 | Compound exhibiting pgd 2 receptor antagonism | CYSLTR2, CYSLTR1, HRH2 | PTGDR2 5/4885TBXA2R 18/4885PTGDR 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.